Avidity Biosciences Target Price

Avidity Biosciences posts a target price of $25. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $25 for RNA means covering analysts, on average, see the stock 179.3% upside of $8.95 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for RNA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Avidity Biosciences's other metric pages and overview cover the third.

Judging Avidity Biosciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $25 here, then scan peer and history charts to see if the gap is persistent.